Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease: Results from the EMPRISE study

被引：0
|
作者：
Koenemann, Lisette [1 ]
Htoo, Phyo Than [2 ,3 ]
Patorno, Elisabetta [2 ,3 ]
Tesfaye, Helen [2 ,3 ]
Wexler, Deborah J. [4 ,5 ]
Glynn, Robert J. [2 ,3 ]
Schmedt, Niklas
Deruaz-Luyet, Anouk [6 ]
Schneeweiss, Sebastian [2 ,3 ]
Paik, Julie M. [2 ,3 ]
机构：
[1] Lilly Deutschland GmbH, Global Med Affairs, Bad Homburg, Germany
[2] HMS, BWH, Boston, MA USA
[3] Div Pharmacoepidemiol, Boston, MA USA
[4] HMS, MGH, Boston, MA USA
[5] MGH Diabet Ctr, Boston, MA USA
[6] Boehringer Ingelheim Int GmbH, Corp Dept Global Epidemiol, Ingelheim, Germany
来源：
INNERE MEDIZIN | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P21-09
引用
收藏
页码：S149 / S149
页数：1
相关论文
共 50 条
  • [31] The impact of GLP-1 receptor agonists on metabolic control and diabetic kidney disease progression
    Venda, Joao
    Henriques, Andreia Dos Santos
    Monsanto, Alice
    Pompermayer, Micael
    Leal, Rita
    Alves, Rui
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [32] Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?
    Bellary, Srikanth
    Tahrani, Abd A.
    Barnett, Anthony H.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (11): : 870 - 871
  • [33] Comparative Safety of Empagliflozin in Routine Care Patients: Interim Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Patorno, Elisabetta
    Tesfaye, Helen
    Wexler, Deborah J.
    Glynn, Robert
    Najafzadeh, Mehdi
    Bessette, Lily G.
    Zakoul, Heidi
    Koeneman, Lisette
    Deruaz-Luyet, Anouk
    Schneeweiss, Sebastian
    DIABETES, 2021, 70
  • [34] Cardiovascular Safety of GLP-1 Receptor Agonists (GLP-1-RA) vs. Other Antidiabetic Agents in Routine Care
    Patorno, Elisabetta
    Everett, Brendan
    Goldfine, Allison
    Liu, Jun
    Glynn, Robert
    Kim, Seoyoung
    DIABETES, 2015, 64 : A389 - A389
  • [35] GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
    Isabel del Olmo-Garcia, Maria
    Francisco Merino-Torres, Juan
    JOURNAL OF DIABETES RESEARCH, 2018, 2018
  • [36] SGLT2 inhibitors vs. GLP-1 agonists: Comparative progression of renal disease
    Stevens, Lauren
    Bowe, Andy
    Schwab, Phil
    Tindal, Michael
    Bloomfield, Andrea
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 110 - 110
  • [37] Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
    Norgaard, Caroline H.
    Starkopf, Liis
    Gerds, Thomas A.
    Vestergaard, Peter
    Bonde, Anders N.
    Fosbol, Emil
    Kober, Lars
    Wong, Nathan D.
    Torp-Pedersen, Christian
    Lee, Christina J-Y
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (06) : 549 - 556
  • [38] GLP-1 receptor agonists: new kids in the block of renoprotection for people with type 2 diabetes and chronic kidney disease
    Koufakis, Theocharis
    Popovic, Djordje S.
    Karakasis, Paschalis
    Georgianos, Panagiotis
    Patoulias, Dimitrios
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (15) : 1979 - 1982
  • [39] GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
    Dario Giugliano
    Lorenzo Scappaticcio
    Miriam Longo
    Giuseppe Bellastella
    Katherine Esposito
    Cardiovascular Diabetology, 20
  • [40] GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
    Dieter, Brad P.
    Alicic, Radica Z.
    Tuttle, Katherine R.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2018, 315 (06) : F1519 - F1525
12345